Actively Recruiting
Study of NBTXR3 with Abscopal or RadScopal Radiation and Immunotherapy for Advanced Solid Tumors with Lung or Liver Metastases
Led by M.D. Anderson Cancer Center · Updated on 2026-07-30
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the combination of NBTXR3, radiation therapy, and immunotherapy with Anti PD-1PD-L1 antibodies affects patients with advanced solid tumors that have spread to the lung or liver. This phase III trial aims to study the safety and potential benefits of activating NBTXR3 nanoparticles with two types of radiation, called Abscopal and RadScopal, alongside immunotherapy. The study explores how these treatments may work together to control cancer growth and spread. Participants are randomly assigned to one of two groups. Both groups receive NBTXR3 injected directly into tumors on day 1 and immunotherapy through intravenous infusion on day 8. Starting day 15, one group undergoes Abscopal radiation therapy over 1 to 2 weeks, while the other group receives RadScopal radiation therapy during the same time frame. The immunotherapy cycles repeat every 3 to 6 weeks for up to 2 years, provided the disease does not progress or side effects become unacceptable. After treatment, patients are followed up every 12 weeks for up to 2 years. During the study, participants undergo imaging-guided injections of NBTXR3 into lung or liver tumors and receive scheduled radiation and immunotherapy treatments. Researchers monitor side effects, tumor response using imaging criteria, and time-to-event outcomes. Laboratory tests, lung function assessments, and pregnancy tests are conducted before starting treatment. The main outcomes measured include the incidence of dose-limiting toxicities within 4 weeks after radiation and the objective response rate within 12 weeks. Safety and disease control are followed regularly during treatment and follow-up periods.
CONDITIONS
Brief Title
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
Research Team
N
Nathan Comeaux
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here